Differential Gonadotropin-Releasing Hormone (GnRH) and GnRH Receptor Messenger Ribonucleic Acid Expression Patterns in Different Tissues of the Female Rat across the Estrous Cycle

Schirman-Hildesheim, Tamar D.; Bar, Tzachi; Ben-Aroya, Nurit; Koch, Yitzhak

doi:10.1210/en.2005-0240

Cited by 74 publications

(57 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is evident from this study that alarelin active immunity can dose-dependently promote expressions of LHR proteins in ewe uterus. The findings are consistent with the works of Schirman-Hildesheim et al (2005) and Lopot et al (2008). However, little effect has been elucidated on its molecular mechanism (Leonardo et al 2006).…”

Section: Discussionsupporting

confidence: 93%

GnRHa active immunity regulates expression of LHR protein and development of uteri in ewes

Wei¹,

Ouyang²,

Guli³

et al. 2013

Journal of Applied Animal Research

View full text Add to dashboard Cite

To investigate the LHR protein expressions in the ovine uteri and LH secretion, and to determine whether the alarelin active immunity affects the uterine development in ewes. Twenty-eight ewes (five to six months) were assigned to four experimental groups. Animals in EG-1, EG-2 and EG-3 were subcutaneously injected with 200, 300 and 400 mg alarelin antigens (day 0 and 14), respectively. Animals in the CG were injected with 2.0 mL solvent (day 0 and 14). Uterine horns were dissected aseptically on day 70. The serum LH concentrations were measured using ELISA. Tissue slices were observed and photographed under optical and electron microscopes. The images were measured using Images software. The results showed that the expressions of LHR protein in EGs increased. The level of LHR protein in EG-3 was higher than that in CG (P B0.05). Serum LH concentrations in EGs were lower than that in CG from day 21 to day 45 (P B0.05). Uterine weights in EG-1, EG-2 and EG-3 reduced by 4.66%, 10.20% and 16.63% (PB0.05), respectively. Uterine wall thickness (UWT) in EG-1, EG-2 and EG-3 reduced by 1.41%, 5.84% and 8.75% (P B0.05), respectively. The endometrial epithelium thickness (EET) in EG-1, EG-2 and EG-3 decreased too (P B0.05). The uterine wall shrank obviously and the glandular cavity reduced. The microvilli shortened. The mitochondria and mitochondrial crista decreased. Summarily, alarelin immunity could promote LHR protein expression in the uteri, and decreased serum LH concentrations, including decreased EET, UWT and uterine weights, could affect the uterine microstructure and ultrastructure, resulting in the inhibition of uterine development dose-dependently.

show abstract

Section: Discussionsupporting

confidence: 93%

GnRHa active immunity regulates expression of LHR protein and development of uteri in ewes

Wei¹,

Ouyang²,

Guli³

et al. 2013

Journal of Applied Animal Research

View full text Add to dashboard Cite

show abstract

“…It has been shown that hypothalamic GnRH mRNA expression varies during the estrous cycle, with the highest expression levels in the late afternoon of the proestrous phase [27][28]. Our study, also, showed a peak in hypothalamic GnRH mRNA levels during the proestrous phase in each group.…”

Section: Discussionsupporting

confidence: 75%

Prenatal Exposure of Kisspeptin Antagonist on the GonadotropinReleasing Hormone (GnRH) Expression in Rat Model of Polycystic Ovary Syndrome

Sareh¹,

Zadeh²,

N³

et al. 2017

J Fertil In Vitro IVF Worldw Reprod Med Genet Stem Cell Biol

View full text Add to dashboard Cite

Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. Increased GnRH/luteinizing hormone (LH) pulse frequency is a characteristic of endocrine abnormalities in PCOS. Kisspeptin antagonists reduce LH pulse frequency and amplitude and are hence supposed to slow GnRH neuron activity that may adjust GnRH/LH levels in PCOS conditions. Objective:To investigate the impact of kisspeptin antagonist P271 administration during prenatal life to reduce GnRH expression in adulthood in prenatally androgenized (PNA) rats as a model of PCOS. Materials and methods:PNA rats (n=9) and controls (n=9) received P271 on day 20 of their prenatal life, and they were examined in adulthood (110-120 days). The ability of P271 to alter GnRH mRNA expression, and plasma levels of gonadotropins and steroid hormones were tested using reverse transcription q-Real-time PCR and ELISA methods, respectively. Results:In this study, based on the result of Generalized Estimating Equation (GEE) model, we found that GnRH expression in PCOS+P271 rats decreased compared to PCOS rats in the diestrous phase. In addition, P271 administration reduced gonadal steroid and gonadotropin levels in both PCOS and non-PCOS rats.

show abstract

“…The presence of GNRH-I has been revealed in the ovary of rats (Aten et al 1986, Schirman-Hildelsheim et al 2005, monkeys , and humans (Aten et al 1987). The present investigation confirms that also the ovary of rabbits expresses GNRH-I in the cytoplasm of different cell types, including the luteal cells, independently of the luteal stage examined.…”

Section: Discussionmentioning

confidence: 99%

Expression of type I GNRH receptor and in vivo and in vitro GNRH-I effects in corpora lutea of pseudopregnant rabbits

Zerani¹,

Parillo²,

Brecchia³

et al. 2010

Journal of Endocrinology

View full text Add to dashboard Cite

The expression of type I GNRH receptor (GNRHR-I) and the direct role of GNRH-I on corpora lutea (CL) function were studied in the pseudopregnant rabbit model. Immunohistochemistry evidenced GNRHR-I and GNRH-I in luteal cells at early (day 4 pseudopregnancy)-, mid (day 9)-, and late (day 13)-luteal stages. Real-time RT-PCR and western blotting revealed GNRHR-I mRNA and protein at the three luteal stages. Buserelin in vivo treatment at days 9 and 13 decreased plasma progesterone levels for 48 and 24 h respectively. In in vitro cultured CL, buserelin reduced progesterone secretion, increased prostaglandin F 2a (PGF 2a ) secretion and cyclooxygenase-2 (COX-2) and nitric oxide synthase (NOS) activities at days 9 and 13, and decreased PGE 2 at day 13. Co-incubation with antagonists for GNRH-I (antide), inositol 1,4,5-trisphosphate (IP 3 , 2-amino-ethoxydiphenylborate), and diacylglycerol (DAG, 1-hexadecyl-2-acetyl glycerol) or inhibitors for phospholipase C (PLC, compound 48/80), and protein kinase C (PKC, staurosporine) counteracted the buserelin effects. Buserelin co-incubated with COX inhibitor (acetylsalicylic acid) increased progesterone and decreased PGF 2a and NOS activity at days 9 and 13, whereas co-incubation with NOS inhibitor (N-nitro-L-arginine methyl ester) increased progesterone at the same luteal stages. These results suggest that GNRHR-I is constitutively expressed in rabbit CL independently of luteal stage, whereas GNRH-I down-regulates directly CL progesterone production via PGF 2a at mid-and late-luteal stages of pseudopregnancy, utilizing its cognate type I receptor with a post-receptorial mechanism that involves PLC, IP 3 , DAG, PKC, COX-2, and NOS.

show abstract

Differential Gonadotropin-Releasing Hormone (GnRH) and GnRH Receptor Messenger Ribonucleic Acid Expression Patterns in Different Tissues of the Female Rat across the Estrous Cycle

Cited by 74 publications

References 57 publications

GnRHa active immunity regulates expression of LHR protein and development of uteri in ewes

GnRHa active immunity regulates expression of LHR protein and development of uteri in ewes

Prenatal Exposure of Kisspeptin Antagonist on the GonadotropinReleasing Hormone (GnRH) Expression in Rat Model of Polycystic Ovary Syndrome

Expression of type I GNRH receptor and in vivo and in vitro GNRH-I effects in corpora lutea of pseudopregnant rabbits

Contact Info

Product

Resources

About